List view / Grid view

Articles

Boom times for pharma M&A

18 February 2021 | By

Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…

Biosimilar uptake: a clinician’s perspective

18 February 2021 | By

To ensure that clinicians buy into biosimilars, it is important that they understand how products are analysed and compared to the originator molecules. Dr Fraser Cummings and Jonathan Sweeting discussed this issue at a recent virtual roundtable event, where they highlighted the complexities of biosimilar development pathways and approval processes. Here, Nikki Withers shares the…

Promising biocompatible and biodegradable drug nanocarriers for cancer treatment and bone defect repair

17 February 2021 | By ,

Drug nanocarriers based on calcium phosphates and calcium silicates have attracted much interest in recent years owing to their excellent biocompatibility and biodegradability, high drug loading capacity, sustained and targeted drug delivery and promising applications in cancer therapy and bone defect repair. However, the research on drug-carrier interactions is a…

The importance of disaccharide excipients in biologics

17 February 2021 | By , ,

Many biologic formulations use a variety of high-purity injectable grade disaccharide excipients to ensure functionality and stability of the final product. In this article, Sunil Kumar Nataraj, Bastiaan Dickhoff and Thontesh GC explore the use of these sugars in the stabilisation of biologics and provide recommendations to manufacturers for enhancing…